GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Profound Medical Corp (TSX:PRN) » Definitions » Cyclically Adjusted Revenue per Share

Profound Medical (TSX:PRN) Cyclically Adjusted Revenue per Share : C$0.56 (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Profound Medical Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Profound Medical's adjusted revenue per share for the three months ended in Mar. 2025 was C$0.125. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$0.56 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-22), Profound Medical's current stock price is C$7.18. Profound Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was C$0.56. Profound Medical's Cyclically Adjusted PS Ratio of today is 12.82.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Profound Medical was 28.52. The lowest was 11.46. And the median was 19.35.


Profound Medical Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Profound Medical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Profound Medical Cyclically Adjusted Revenue per Share Chart

Profound Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.56

Profound Medical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.54 0.54 0.56 0.56

Competitive Comparison of Profound Medical's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Profound Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Profound Medical's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Profound Medical's Cyclically Adjusted PS Ratio falls into.


;
;

Profound Medical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Profound Medical's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.125/129.1809*129.1809
=0.125

Current CPI (Mar. 2025) = 129.1809.

Profound Medical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 0.000 101.449 0.000
201703 0.107 102.634 0.135
201706 0.177 103.029 0.222
201709 0.235 103.345 0.294
201712 0.256 103.345 0.320
201803 0.049 105.004 0.060
201806 0.020 105.557 0.024
201809 0.028 105.636 0.034
201812 0.151 105.399 0.185
201903 0.137 106.979 0.165
201906 0.054 107.690 0.065
201909 0.062 107.611 0.074
201912 0.234 107.769 0.280
202003 0.110 107.927 0.132
202006 0.086 108.401 0.102
202009 0.158 108.164 0.189
202012 0.187 108.559 0.223
202103 0.044 110.298 0.052
202106 0.158 111.720 0.183
202109 0.158 112.905 0.181
202112 0.061 113.774 0.069
202203 0.083 117.646 0.091
202206 0.125 120.806 0.134
202209 0.130 120.648 0.139
202212 0.082 120.964 0.088
202303 0.122 122.702 0.128
202306 0.101 124.203 0.105
202309 0.110 125.230 0.113
202312 0.126 125.072 0.130
202403 0.080 126.258 0.082
202406 0.125 127.522 0.127
202409 0.156 127.285 0.158
202412 0.231 127.364 0.234
202503 0.125 129.181 0.125

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Profound Medical  (TSX:PRN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Profound Medical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=7.18/0.56
=12.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Profound Medical was 28.52. The lowest was 11.46. And the median was 19.35.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Profound Medical Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Profound Medical's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Profound Medical Business Description

Traded in Other Exchanges
Address
2400 Skymark Avenue, Unit 6, Mississauga, ON, CAN, L4W 5K5
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Executives
Dr. Arun Menawat Director, Senior Officer
Thomas Michael Tamberrino Senior Officer
Rashed Osman Dewan Senior Officer
Abbey Klair Goodman Senior Officer
Brian Ellacott Director
Murielle Lortie Director
Arthur Lee Rosenthal Director
Aaron Davidson Senior Officer
Guruprit Kour Singh Senior Officer
Ian Heynen Senior Officer

Profound Medical Headlines